Clavis/Clovis' Pancreatic Cancer Drug Fails Despite Personalized Medicine Approach
This article was originally published in The Pink Sheet Daily
Executive Summary
The failure of Clavis Pharma's and Clovis Oncology's novel potential pancreatic cancer therapy CP-4126/CO-101 in the pivotal LEAP trial was associated with the surprising failure of a novel personalized medicine approach to treating the devastating disease.
You may also be interested in...
Clovis Highlights Pipeline Turnaround Going Into 2014
The small oncology company has recovered from previous setbacks and is now anticipating a strong year to come as it moves two drugs into later-stage development and pivotal trials.
Clovis Highlights Pipeline Turnaround Going Into 2014
The small oncology company has recovered from previous setbacks and is now anticipating a strong year to come as it moves two drugs into later-stage development and pivotal trials.
Biopharma Dealmaking Quarterly Statistics, Q2 2013
Q2 2013 biopharma financing increased 139% to $11 billion over Q1’s $4.6 billion, thanks mostly to two huge transactions by Valeant to fund its $8.7 billion takeover of ophthalmics player Bausch & Lomb, the company’s largest acquisition to date. Options and antibody-drug conjugates featured prominently in the alliances.